Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 714,471 shares, a decline of 40.5% from the July 30th total of 1,200,354 shares. Based on an average daily volume of 271,896 shares, the short-interest ratio is currently 2.6 days. Currently, 4.8% of the shares of the company are sold short.

Institutional Trading of Cel-Sci

Several large investors have recently added to or reduced their stakes in CVM. HighTower Advisors LLC purchased a new position in Cel-Sci in the 4th quarter worth approximately $53,000. HRT Financial LP bought a new stake in shares of Cel-Sci during the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in shares of Cel-Sci during the fourth quarter valued at approximately $66,000. US Bancorp DE purchased a new position in shares of Cel-Sci in the third quarter worth $80,000. Finally, Renaissance Technologies LLC bought a new position in shares of Cel-Sci during the fourth quarter worth $81,000. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Stock Performance

CVM traded up $0.02 during mid-day trading on Wednesday, reaching $1.63. 38,276 shares of the company traded hands, compared to its average volume of 260,417. The company’s fifty day moving average price is $1.33 and its 200-day moving average price is $2.35. The stock has a market capitalization of $28.49 million, a P/E ratio of -0.17 and a beta of 0.61. The company has a quick ratio of 1.42, a current ratio of 1.48 and a debt-to-equity ratio of 0.35. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $12.68.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.47) EPS for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.